历史上，FDA 要求药物发现与开发项目必须包含动物试验。这一要求已随 2022 年 FDA Modernization Act 的通过而终止。This change has opened the door for expanded use of alternatives to animal testing including biosimulation, organ-on-a-chip, and cell based assays.

In this panel discussion with Nasdaq’s David Wicks and Certara’s Dr. Jim Herman and Dr. Hannah Jones, they will discuss how scientists can use innovative, leading-edge technologies more fully in future drug discovery and development strategies.  By attending this interactive webinar, you will learn:

• How physiologically-based pharmacokinetic (PBPK) modeling can help bridge the chasm between pre-clinical and clinical development
• Best practices in toxicology to streamline non-clinical development and assessment of drug safety
• The coming trends in the pharmaceutical industry to support the 3Rs of animal testing (reduce, refine, replace)